首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL27A |
| Uniprot No | Q8NEV9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 29-243aa |
| 氨基酸序列 | FP RPPGRPQLSL QELRREFTVS LHLARKLLSE VRGQAHRFAE SHLPGVNLYL LPLGEQLPDV SLTFQAWRRL SDPERLCFIS TTLQPFHALL GGLGTQGRWT NMERMQLWAM RLDLRDLQRH LRFQVLAAGF NLPEEEEEEE EEEEEERKGL LPGALGSALQ GPAQVSWPQL LSTYRLLHSL ELVLSRAVRE LLLLSKAGHS VWPLGFPTLS PQP |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL27A重组蛋白的3篇示例参考文献(内容为虚构示例，仅供参考格式)：
---
1. **文献名称**: *Recombinant IL27A Enhances Antitumor Immunity by Modulating T Cell Responses*
**作者**: Zhang L, et al.
**摘要**: 本研究探讨了重组IL27A蛋白通过激活CD8+ T细胞和抑制调节性T细胞(Tregs)功能，增强抗肿瘤免疫反应的机制。动物模型显示其显著抑制黑色素瘤生长。
2. **文献名称**: *Structural and Functional Characterization of Human IL27A Protein Expressed in HEK293 Cells*
**作者**: Smith J, et al.
**摘要**: 报道了利用HEK293细胞系统高效表达人源IL27A重组蛋白的方法，并通过X射线晶体学解析其三维结构，揭示了其与受体结合的分子机制。
3. **文献名称**: *IL27A Recombinant Protein Attenuates Autoimmune Encephalomyelitis via Suppressing Th17 Differentiation*
**作者**: Tanaka K, et al.
**摘要**: 实验证明重组IL27A可通过抑制IL-6/STAT3通路降低Th17细胞分化，显著缓解多发性硬化症模型小鼠的神经炎症症状。
---
注：以上文献为示例，实际引用需检索PubMed等数据库获取真实研究(可尝试关键词：IL27A recombinant protein, therapeutic, structure)。
IL27A recombinant protein is a biologically active cytokine produced through recombinant DNA technology, designed to mimic the function of native interleukin-27 (IL-27). IL-27 is a heterodimeric cytokine belonging to the IL-12 family, composed of two subunits: IL27p28 (encoded by the IL27A gene) and EBI3 (Epstein-Barr virus-induced gene 3). It is primarily secreted by antigen-presenting cells, such as dendritic cells and macrophages, and plays a dual role in modulating immune responses.
IL-27 regulates T-cell differentiation, balancing pro-inflammatory Th1/Th17 responses and anti-inflammatory Treg activity. It signals through a receptor complex of IL-27Rα (WSX-1) and gp130. activating JAK-STAT pathways, particularly STAT1 and STAT3. This cytokine is implicated in autoimmune diseases (e.g., multiple sclerosis, colitis) and cancer immunotherapy, where it can either suppress pathological inflammation or enhance antitumor immunity depending on context.
Recombinant IL27A protein is typically expressed in mammalian systems (e.g., HEK293 cells) to ensure proper glycosylation and bioactivity. Its applications include studying IL-27-mediated signaling, immune cell crosstalk, and therapeutic potential in preclinical models. Recent research highlights its ability to inhibit pathogenic T cells while promoting cytotoxic CD8+ T-cell responses, making it a candidate for immune-modulatory therapies. However, its pleiotropic effects necessitate precise dose and timing optimization in clinical settings. Current studies also explore engineered IL-27 variants to improve stability or target specificity.
×
